What is the role of protective therapies in association with administration of traditional nonsteroidal antiinflammatory drugs?
To date, only misoprostol has been proved to reduce the risk for serious GI toxicity. Misoprostol diminishes the incidence of endoscopically detectable lesions. However, no evidence has confirmed that misoprostol diminishes the risk of complications from the lesions when they occur. Protective agents may be indicated in patients over the age of 60 years of age and patients with predisposition to GI problems.